- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01280539
The Effect of Transcutaneous Electrical Nerve Stimulation (TENS) in Multiple Sclerosis
September 4, 2012 updated by: Koen Cuypers, Hasselt University
In this study the researchers want to investigate the effects of long-term transcutaneous electrical nerve stimulation on the cortical excitability of persons with multiple sclerosis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Limburg
-
Diepenbeek, Limburg, Belgium, 3590
- Hasselt University (BIOMED)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 68 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Expanded Disability Status Scale (EDSS) scores between 2 and 6.5
- Stable MS (no relapse during the last 3 months before study onset)
- sensory impairment
- age: between 18 and 68 years old
Exclusion Criteria:
- Patients with other pathologies associated with peripheral and/or central sensory dysfunction or under psychotropic or antiepileptic medication
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TENS
Transcutaneous electrical nerve stimulation will be applied on the impaired hand
|
3 weeks, 5 times a week, 60 minutes a day.
|
Sham Comparator: Sham TENS
Sham TENS will be applied to the impaired hand
|
3 weeks, 5 times a week, 60 minutes a day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in cortical excitability
Time Frame: Baseline, immediately after and 3 weeks after the intervention
|
Cortical excitability will be assessed using transcranial magnetic stimulation (TMS)
|
Baseline, immediately after and 3 weeks after the intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2011
Primary Completion (Actual)
January 1, 2012
Study Completion (Actual)
June 1, 2012
Study Registration Dates
First Submitted
January 19, 2011
First Submitted That Met QC Criteria
January 19, 2011
First Posted (Estimate)
January 20, 2011
Study Record Updates
Last Update Posted (Estimate)
September 5, 2012
Last Update Submitted That Met QC Criteria
September 4, 2012
Last Verified
September 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MECU2012-002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
Clinical Trials on Transcutaneous electrical nerve stimulation
-
University of L'AquilaCompleted
-
Karolinska University HospitalActive, not recruitingHip Fractures | Hip Osteoarthritis | Orthopedic Disorder | Post Operative PainSweden
-
University of Colorado, BoulderUniversity of Colorado, Denver; Colorado State UniversityWithdrawn
-
ADIR AssociationCompletedChronic Obstructive Pulmonary DiseaseFrance
-
Assistance Publique - Hôpitaux de ParisCompletedTendinopathy | Cervical Radiculopathy | Post-herpetic Neuralgia | Chronic Back Pain | Limbs Arthrosis | Non Arthrosic Limbs Arthralgia | Chronic Lomboradiculalgia | Post-surgical Peripheral Neuropathic Pain | Post Trauma Neuropathic Pain | Complex Regional Pain Syndrome Type I or IIFrance
-
University Hospital, ToulouseMinistry of Health, FranceTerminatedPeripheral Artery DiseaseFrance
-
Secretaria Municipal de Saúde de RolanteCentro Universitario La SalleUnknown
-
University of Nove de JulhoRecruiting
-
Institut Cancerologie de l'OuestTerminated
-
Hawra Al-DandanRecruitingOveractive Bladder SyndromeSaudi Arabia